Effects of Dexmedetomidine and Remimazolam Based Sedation on Perioperative Outcomes after Transcatheter Aortic Valve Replacement under Monitored Anesthesia Care

Effects of Dexmedetomidine and Remimazolam Based Sedation on Perioperative Outcomes after Transcatheter Aortic Valve Replacement under Monitored Anesthesia Care - A Single Blind Randomized Controlled Trial -

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0012282

Enrollment

114

Registered

2026-07-15

Start date

2026-07-09

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In the dexmedetomidine group, sedation will be induced with an intravenous loading dose of 1 µg/kg administered over 10 minutes, followed by a continuous infusion at a maintenance dose of 0.2–0

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A patient scheduled for transcatheter aortic valve replacement under monitored anesthesia care.

Exclusion criteria

Exclusion criteria: (1) Age under 19 or over 100 years (2) Pregnant women (3) Allergy or contraindication to the study drugs (4) Preoperative mental status not alert or inability to communicate (5) Morbid obesity with a body mass index (BMI) exceeding 35 kg/m² (6) ASA physical status classification V or higher (7) Use of vasopressors or hemodynamic support devices (e.g., IABP, ECMO, pacemaker) (8) Refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Quality of Recovery	—

Secondary

Measure	Time frame
Delirium, Acute kidney injury, nausea and vomiting, pulmonary complications	—

Countries

Korea, Republic of

Contacts

Public ContactDoh Yoon Kim

Kyung Hee University Hospital

dlmddyk@gmail.com+82-2-958-8589

Outcome results